ESMO 2024
September 13-17, 2024

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.

Content to be used in accordance with local CPO guidelines

Breast cancer

Breast cancer

List of Presentations

Breast Cancer Prostate Cancer NET Other Radiosensitive Cancer Melanoma

Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients (Pts) With HR+/HER2− Early Breast Cancer (EBC): 4-Year Outcomes From the NATALEE Trial

Peter A. Fasching*, Daniil Stroyakovskiy, Denise A. Yardley, Chiun-Sheng Huang, John Crown, Aditya Bardia, Stephen Chia, Seock-Ah Im, Miguel Martin, Binghe Xu, Sherene Loi, Carlos Barrios, Michael Untch, Rebecca Moroose, Frances Visco, Gabriel N. Hortobagyi, Dennis Slamon, Yanina Oviedo, Sorcha Waters, Sara Hurvitz

  • Presentation #LBA13 – Proffered Paper
    Barcelona Auditorium - Hall 2 | Monday, September 16, 2024 | 11:15-11:25 CEST (Proffered Paper Presentation) | 11:25-11:35 CEST (Discussion)

  • Abstract
This presentation will be available once the congress embargo lifts

Efficacy and Safety of Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) in Younger Patients (pts) with HR+/HER2− Early Breast Cancer (EBC) in NATALEE

Sherene Loi*, Erica Stringer Reasor, Jean Sebastien Frenel, Mattea Reinisch, Ruth O’Regan, Michelino De Laurentiis, Yeon Hee Park, Anne O’Dea, Yen-Shen Lu, Valeria Gonzalez, Melissa Gao, Sorcha Waters, Huilin Hu, Binghe Xu

  • Presentation #235MO – Mini Oral
    Barcelona Auditorium - Hall 2 | Saturday, September 14, 2024 | 10:25 - 10:30 CEST (Mini Oral Presentation) | 10:30 - 10:45 CEST (Discussion)

  • Abstract
This presentation will be available once the congress embargo lifts

Efficacy and Safety of Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) in Older Patients (pts) with HR+/HER2− Early Breast Cancer (EBC) in NATALEE

Michael Untch*, Denise A. Yardley, Seock-Ah Im, Timothy J. Pluard, Lowell Hart, John Crown, Gilles Freyer, Claudio Zamagni, Isabel Blancas, Federico Parnizari, Melissa Gao, Khalid Amin, Huilin Hu, Hope S. Rugo

  • Presentation #240P – Poster
    Hall 6 | Monday, September 16, 2024 | 09:00 - 17:00 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

Clinical Outcomes in Patients (pts) with HR+/HER2− Early Breast Cancer (EBC) By Prior Systemic Treatment (tx): A Subgroup Analysis of the NATALEE Trial

Nicholas McAndrew*, Stephen Chia, Fabio Puglisi, Aditya Bardia, Yann Izarzugaza, Christian Schem, Binghe Xu, Fanny Le Du, Priyanka Sharma, Karen Afenjar, Murat Akdere, Juan Pablo Zarate, Yogesh Chattar, Peter Fasching

  • Presentation #242P – Poster
    Hall 6 | Monday, September 16, 2024 | 09:00 - 17:00 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

Real-world Evidence on Risk of Recurrence (ROR) in Patients (pts) with Node-negative (N0) and Node-positive HR+/HER2– Early Breast Cancer (EBC) from US Electronic Health Records (EHR)

Komal Jhaveri*, Mark Pegram, Patrick Neven, Giuseppe Curigliano, Laura Spring, Joseph Gligorov, Ilana Schlam, Nadia Harbeck, Dejan Juric, Elgene Lim, Shusen Wang, Henry Owusu, Murat Akdere, Fen Ye, Julia Kim, Fatima Cardoso

  • Presentation #292P – Poster
    Hall 6 | Monday, September 16, 2024 | 09:00 - 17:00 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

Characteristics of Real-world (RW) NATALEE and MonarchE eligible Populations: A US Electronic Health Records (EHR) Database Analysis

Paolo Tarantino*, Hope S. Rugo, Giuseppe Curigliano, Joyce O’Shaughnessy, Wolfgang Janni, Komal Jhaveri, Jason Mouabbi, Adam Brufsky, Erika Hamilton, Ruth O’Regan, Liz Santarsiero, Eleanor Sum, Andrew Scotchmer, Fen Ye, Stephanie L. Graff

  • Presentation #245P – Poster
    Hall 6 | Monday, September 16, 2024 | 09:00 - 17:00 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

Breast Cancer Lighthouse Non-interventional Hybrid Real-world Study: Molecular Characterization and 2-year Effectiveness Data

Ângela Margarida Nogal Dias, Leonor Matos, Beatriz Gosalbez, Sofia Braga*, Leonor Pinto, António Pêgo, Catarina Abreu, Marta Ferreira, Patrícia Gago, Ilda Faustino, Idília Pina, Cristiana Marques, José Luis Passos Coelho, Francisco Branco, Joana Simões, Inês Vaz-Luis, Fernando Schmitt, Luis Costa, Marco Domingues, Daniel Brás

  • Presentation #410P – Poster
    Hall 6 | Monday, September 16, 2024 | 09:00 - 17:00 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

*Presenting Author
View list of select presentations for this compound